Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm

References

• Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655–2664.
   PubMed Web of Science ®Google Scholar
• Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. JCO. 2008;26:3063–3072.
   PubMed Web of Science ®Google Scholar
• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342.
   PubMed Web of Science ®Google Scholar
• Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589–597.
   PubMed Web of Science ®Google Scholar
• Tsai HJ, Wu CC, Tsai CR, et al. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLOS One. 2013;8:e62487.
   PubMed Web of Science ®Google Scholar
• Rindi G, Arnold R, Bosman F, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: IARC Press; 2010. p. 13–14.
   Google Scholar
• Lloyd RV, Osamura RY, KlöPpel G, et al. World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of endocrine organs. 4th edition. Lyon, France: International Agency for Research on Cancer (IARC); 2017.
   Google Scholar
• Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007;42:3–27.
   PubMedGoogle Scholar
• Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045–2051.
   PubMed Web of Science ®Google Scholar
• Atsumi T, Singh R, Sabharwal L, et al. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res. 2014;74:8–14.
   PubMed Web of Science ®Google Scholar
• Cao Y, Nishihara R, Wu K, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016;2:762.
   PubMed Web of Science ®Google Scholar
• Simon TG, Ma Y, Ludvigsson JF, et al. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Onco. 2018;4:1683–1690.
   PubMed Web of Science ®Google Scholar
• Qiao Y, Yang T, Gan Y, et al. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer. 2018;18:288.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602–1612.
   PubMed Web of Science ®Google Scholar
• Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23:1403–1415.
   PubMed Web of Science ®Google Scholar
• Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med. 2007;58:239–252.
   PubMed Web of Science ®Google Scholar
• Zha S, Yegnasubramanian V, Nelson WG, et al. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004;215:1–20.
   PubMed Web of Science ®Google Scholar
• Jana NR. NSAIDs and apoptosis. Cell Mol Life Sci. 2008;65:1295–1301.
   PubMed Web of Science ®Google Scholar
• Stark LA, Reid K, Sansom OJ, et al. Aspirin activates the NF-kappaB signaling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis. 2006;28:968–976.
   PubMed Web of Science ®Google Scholar
• Din FV, Dunlop MG, Stark LA. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signaling and apoptosis. Br J Cancer. 2004;91:381–388.
   PubMed Web of Science ®Google Scholar
• Spampatti M, Vlotides G, Spöttl G, et al. Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells. WJG. 2014;20:10038–10049.
   PubMed Web of Science ®Google Scholar
• Rinzivillo M, Capurso G, Campana D, et al. Risk and protective factors for small intestine neuroendocrine tumors: a prospective case-control study. Neuroendocrinology. 2016;103:531–537.
   PubMed Web of Science ®Google Scholar
• Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401.
   PubMed Web of Science ®Google Scholar
• Din FV, Theodoratou E, Farrington SM, et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 2010;59:1670–1679.
   PubMed Web of Science ®Google Scholar
• Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518–527.
   PubMed Web of Science ®Google Scholar
• Chan AT1, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356:2131–2142.
   PubMed Web of Science ®Google Scholar
• Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91:333–338.
   PubMed Web of Science ®Google Scholar
• Tao Y, Li Y, Liu X, et al. Nonsteroidal anti-inflammatory drugs, especially aspirin, are linked to lower risk and better survival of hepatocellular carcinoma: a meta-analysis. CMAR. 2018;10:2695–2709.
   Google Scholar
• Sun D, Liu H, Dai X, et al. Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition. Cancer Lett. 2017;406:105–115.
   PubMed Web of Science ®Google Scholar
• Din FV, Valanciute A, Houde VP, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142:1504–1515.
   PubMed Web of Science ®Google Scholar
• Mizuno S, Kato K, Hashimoto A, et al. Expression of cyclo-oxygenase-2 in gastrointestinal carcinoid tumors. J Gastroenterol Hepatol. 2006;21:1313–1319.
   PubMed Web of Science ®Google Scholar
• Bergmann F, Breinig M, Höpfner M, et al. Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol. 2009;104:171–181.
   PubMed Web of Science ®Google Scholar
• Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367:1596–1606.
   PubMed Web of Science ®Google Scholar
• Zitzmann K, De Toni EN, Brand S, et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology. 2007;85:54–60.
   PubMed Web of Science ®Google Scholar
• Grozinsky-Glasberg S, Franchi G, Teng M, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology. 2008;87:168–181.
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–523.
   PubMed Web of Science ®Google Scholar
• Massironi S, Sciola V, Peracchi M, et al. Neuroendocrine tumors of the gastro-entero-pancreatic system. WJG. 2008;14:5377–5384.
   PubMed Web of Science ®Google Scholar
• Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2009;89:471–476.
   PubMed Web of Science ®Google Scholar
• Durante C, Boukheris H, Dromain C, et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer. 2009;16:585–597.
   PubMed Web of Science ®Google Scholar
• Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083–1092.
   PubMed Web of Science ®Google Scholar
• Saxena A, Chua TC, Chu F, et al. Optimizing the surgical effort in patients with advanced neuroendocrine neoplasm hepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation. Am J Clin Oncol. 2012;35:439–445.
   PubMed Web of Science ®Google Scholar
• Panzuto F, Merola E, Rinzivillo M, et al. Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. Pancreas. 2014;43:212–218.
   PubMed Web of Science ®Google Scholar